Acceptable Use Policy

1. Clinical integrity

The clinical workflow is not optional and cannot be routed around.

• No prescription may be issued without review by a provider licensed in the patient's state.
• You may not pressure, incentivise or instruct providers toward a prescribing outcome.
• You may not disable, bypass or misconfigure eligibility screening to increase approval rates.
• You may not present a workflow to patients as clinical review when no clinician reviews it.
• Where a therapy requires labs or a live visit before a first fill, that requirement may not be waived commercially.

2. Catalog restrictions

• Only compounds that are lawfully prescribable and dispensable by a licensed pharmacy may be offered.
• No research-use-only positioning. If something cannot be prescribed and dispensed properly, it does not belong in a storefront on this platform.
• Compounded preparations may not be described as FDA-approved, nor as generic or equivalent versions of an approved branded product.
• You may not offer a therapy into a state where it is not lawfully available.

3. Marketing and claims

In these categories, regulatory exposure comes from marketing more often than from medicine.

• Outcome claims must be substantiated before publication.
• Testimonials must be genuine, representative and disclosed where required.
• Before-and-after imagery must be real and must not imply typical results that are not typical.
• Pricing must be presented accurately, including recurring charges and what triggers them.
• You may not imply endorsement by, or affiliation with, any regulator, manufacturer or platform.

4. Patient data

• Protected health information may only be handled in the flows the platform provides for it.
• You may not export PHI into general-purpose marketing, analytics or messaging tools that are not covered by a BAA.
• You may not segment patient lists by condition or treatment inside tools that lack a BAA.
• You may not attempt to re-identify de-identified data.

5. Technical conduct

• No attempt to gain unauthorised access to the platform, other tenants, or any data that is not yours.
• No probing, scanning or load testing without written authorisation.
• No reverse engineering, scraping or benchmarking for a competing product without consent.
• No use of the platform to send unsolicited bulk messaging.

6. Enforcement

Where we identify a breach we will normally contact you and give an opportunity to correct it. Where a breach presents a risk to patients, to licensure, or to the platform's regulatory standing, we may suspend the affected functionality or the account immediately.

To report a suspected violation, write to support@pharmabro.co.